Previous Close | 0.0500 |
Open | 0.0500 |
Bid | 0.0000 |
Ask | 0.0500 |
Strike | 5.00 |
Expire Date | 2024-05-17 |
Day's Range | 0.0500 - 0.0500 |
Contract Range | N/A |
Volume | |
Open Interest | 643 |
Amidst a significant net loss increase, Omeros Corp navigates through promising drug trials and strategic royalty milestones.
SEATTLE, May 15, 2024--Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders, today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2024, which include: